These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11814453)

  • 1. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions.
    de Ferranti S; Rifai N
    Clin Chim Acta; 2002 Mar; 317(1-2):1-15. PubMed ID: 11814453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study.
    Seven E; Husemoen LL; Sehested TS; Ibsen H; Wachtell K; Linneberg A; Jeppesen JL
    PLoS One; 2015; 10(6):e0128987. PubMed ID: 26035431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Di Napoli M; Schwaninger M; Cappelli R; Ceccarelli E; Di Gianfilippo G; Donati C; Emsley HC; Forconi S; Hopkins SJ; Masotti L; Muir KW; Paciucci A; Papa F; Roncacci S; Sander D; Sander K; Smith CJ; Stefanini A; Weber D
    Stroke; 2005 Jun; 36(6):1316-29. PubMed ID: 15879341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The associations between current recommendation for physical activity and cardiovascular risks associated with obesity.
    Akbartabartoori M; Lean ME; Hankey CR
    Eur J Clin Nutr; 2008 Jan; 62(1):1-9. PubMed ID: 17342166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.
    Soedamah-Muthu SS; Livingstone SJ; Charlton-Menys V; Betteridge DJ; Hitman GA; Neil HA; Bao W; DeMicco DA; Preston GM; Fuller JH; Stehouwer CD; Schalkwijk CG; Durrington PN; Colhoun HM;
    Diabetologia; 2015 Jul; 58(7):1494-502. PubMed ID: 25899452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: findings from the 1999-2004 NHANES.
    Veeranna V; Zalawadiya SK; Panaich S; Patel KV; Afonso L
    Int J Cardiol; 2013 Oct; 168(6):5156-61. PubMed ID: 24016543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
    Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
    Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Connecting the role of C-reactive protein and statins in cardiovascular disease.
    Ridker PM
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III39-44. PubMed ID: 12708638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological distress as a risk factor for cardiovascular events: pathophysiological and behavioral mechanisms.
    Hamer M; Molloy GJ; Stamatakis E
    J Am Coll Cardiol; 2008 Dec; 52(25):2156-62. PubMed ID: 19095133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension.
    Shankar A; Li J; Nieto FJ; Klein BE; Klein R
    Am Heart J; 2007 Sep; 154(3):495-501. PubMed ID: 17719297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly.
    Nadrowski P; Chudek J; Skrzypek M; Puzianowska-Kuźnicka M; Mossakowska M; Więcek A; Zdrojewski T; Grodzicki T; Kozakiewicz K
    Exp Gerontol; 2016 Dec; 85():112-117. PubMed ID: 27729238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.